40. R.M. Lu, Y.L. Chang, M.S. Chen, H.C. Wu, Single chain anti-c-Met antibody conjugated
nanoparticles for in vivo tumor-targeted imaging and drug delivery. Biomaterials 32(12),
3265–3274 (2011)
41. D.S. Wilson, J.W. Szostak, In vitro selection of functional nucleic acids. Annu. Rev.
Biochem. 68, 611–647 (1999)
42. S.E. Lupold, B.J. Hicke, Y. Lin, D.S. Coffey, Identification and characterization of
nuclease-stabilized RNA molecules that bind human prostate cancer cells via the
prostate-specific membrane antigen. Cancer Res. 62(14), 4029–4033 (2002)
43. O.C. Farokhzad, S.Y. Jon, A. Khademhosseini, T.N.T. Tran, D.A. LaVan, R. Langer,
Nanopartide-aptamer bioconjugates: a new approach for targeting prostate cancer cells.
Cancer Res. 64(21), 7668–7672 (2004)
44. V. Bagalkot, L. Zhang, E. Levy-Nissenbaum, S. Jon, P.W. Kantoff, R. Langer et al., Quantum
dot—aptamer conjugates for synchronous cancer imaging, therapy, and sensing of drug
delivery based on Bi-fluorescence resonance energy transfer. Nano Lett. 7(10), 3065–3070
(2007)
45. U. Gunthert, M. Hofmann, W. Rudy, S. Reber, M. Zoller, I. Haussmann et al., A new variant
of glycoprotein CD44 confers metastatic potential to rat carcinoma-cells. Cell 65(1), 13–24
(1991)
46. W.T. Wu, J. Shen, P. Banerjee, S.Q. Zhou, Core-shell hybrid nanogels for integration of
optical temperature-sensing, targeted tumor cell imaging, and combined chemo-photothermal
treatment. Biomaterials 31(29), 7555–7566 (2010)
47. D.W. Hwang, H.Y. Kim, F.Y. Li, J.Y. Park, D. Kim, J.H. Park et al., In vivo visualization of
endogenous miR-21 using hyaluronic acid-coated graphene oxide for targeted cancer therapy.
Biomaterials 121, 144–154 (2017)
48. A. Garg, A.W. Tisdale, E. Haidari, E. Kokkoli, Targeting colon cancer cells using PEGylated
liposomes modified with a fibronectin-mimetic peptide. Int. J. Pharm. 366(1–2), 201–210
(2009)
49. M.E. Gindy, S.X. Ji, T.R. Hoye, A.Z. Panagiotopoulos, R.K. Prud’homme, Preparation of
poly(ethylene glycol) protected nanoparticles with variable bioconjugate ligand density.
Biomacromol 9(10), 2705–2711 (2008)
50. V. Olivier, I. Meisen, B. Meckelein, T.R. Hirst, J. Peter-Katalinic, M.A. Schmidt et al.,
Influence of targeting ligand flexibility on receptor binding of particulate drug delivery
systems. Bioconjug. Chem. 14(6), 1203–1208 (2003)
51. M. Ferrari, Beyond drug delivery. Nat. Nanotechnol. 3(3), 131–132 (2008)
52. F. Gu, L. Zhang, B.A. Teply, N. Mann, A. Wang, A.F. Radovic-Moreno et al., Precise
engineering of targeted nanoparticles by using self-assembled biointegrated block copolymers. Proc. Natl. Acad. Sci. U.S.A. 105(7), 2586–2591 (2008)
53. H. Shmeeda, D. Tzernach, L. Mak, A. Gabizon, Her2-targeted pegylated liposomal
doxorubicin: retention of target-specific binding and cytotoxicity after in vivo passage.
J. Control Release 136(2), 155–160 (2009)
54. J.H. Park, G. von Maltzahn, L.L. Zhang, A.M. Derfus, D. Simberg, T.J. Harris et al.,
Systematic surface engineering of magnetic nanoworms for in vivo tumor targeting. Small
5(6), 694–700 (2009)
55. S. Jeong, J.Y. Park, M.G. Cha, H. Chang, Y.I. Kim, H.M. Kim et al., Highly robust and
optimized conjugation of antibodies to nanoparticles using quantitatively validated protocols.
Nanoscale 9(7), 2548–2555 (2017)
56. D. Zeng, N.S. Lee, Y. Liu, D. Zhou, C.S. Dence, K.L. Wooley et al.,
64
Cu core-labeled
nanoparticles with high specific activity via metal-free click chemistry. ACS Nano 6(6),
5209–5219 (2012)
57. S.B. Lee, H.L. Kim, H.J. Jeong, S.T. Lim, M.H. Sohn, D.W. Kim, Mesoporous silica
nanoparticle pretargeting for PET imaging based on a rapid bioorthogonal reaction in a living
body. Angew. Chem. Int. Ed. Engl. 52(40), 10549–10552 (2013)
58. W.G. Kreyling, A.M. Abdelmonem, Z. Ali, F. Alves, M. Geiser, N. Haberl et al., In vivo
integrity of polymer-coated gold nanoparticles. Nat. Nanotechnol. 10(7), 619–623 (2015)
12 Click Chemistry for Radionanomedicine Platform
249
nanoparticles for in vivo tumor-targeted imaging and drug delivery. Biomaterials 32(12),
3265–3274 (2011)
41. D.S. Wilson, J.W. Szostak, In vitro selection of functional nucleic acids. Annu. Rev.
Biochem. 68, 611–647 (1999)
42. S.E. Lupold, B.J. Hicke, Y. Lin, D.S. Coffey, Identification and characterization of
nuclease-stabilized RNA molecules that bind human prostate cancer cells via the
prostate-specific membrane antigen. Cancer Res. 62(14), 4029–4033 (2002)
43. O.C. Farokhzad, S.Y. Jon, A. Khademhosseini, T.N.T. Tran, D.A. LaVan, R. Langer,
Nanopartide-aptamer bioconjugates: a new approach for targeting prostate cancer cells.
Cancer Res. 64(21), 7668–7672 (2004)
44. V. Bagalkot, L. Zhang, E. Levy-Nissenbaum, S. Jon, P.W. Kantoff, R. Langer et al., Quantum
dot—aptamer conjugates for synchronous cancer imaging, therapy, and sensing of drug
delivery based on Bi-fluorescence resonance energy transfer. Nano Lett. 7(10), 3065–3070
(2007)
45. U. Gunthert, M. Hofmann, W. Rudy, S. Reber, M. Zoller, I. Haussmann et al., A new variant
of glycoprotein CD44 confers metastatic potential to rat carcinoma-cells. Cell 65(1), 13–24
(1991)
46. W.T. Wu, J. Shen, P. Banerjee, S.Q. Zhou, Core-shell hybrid nanogels for integration of
optical temperature-sensing, targeted tumor cell imaging, and combined chemo-photothermal
treatment. Biomaterials 31(29), 7555–7566 (2010)
47. D.W. Hwang, H.Y. Kim, F.Y. Li, J.Y. Park, D. Kim, J.H. Park et al., In vivo visualization of
endogenous miR-21 using hyaluronic acid-coated graphene oxide for targeted cancer therapy.
Biomaterials 121, 144–154 (2017)
48. A. Garg, A.W. Tisdale, E. Haidari, E. Kokkoli, Targeting colon cancer cells using PEGylated
liposomes modified with a fibronectin-mimetic peptide. Int. J. Pharm. 366(1–2), 201–210
(2009)
49. M.E. Gindy, S.X. Ji, T.R. Hoye, A.Z. Panagiotopoulos, R.K. Prud’homme, Preparation of
poly(ethylene glycol) protected nanoparticles with variable bioconjugate ligand density.
Biomacromol 9(10), 2705–2711 (2008)
50. V. Olivier, I. Meisen, B. Meckelein, T.R. Hirst, J. Peter-Katalinic, M.A. Schmidt et al.,
Influence of targeting ligand flexibility on receptor binding of particulate drug delivery
systems. Bioconjug. Chem. 14(6), 1203–1208 (2003)
51. M. Ferrari, Beyond drug delivery. Nat. Nanotechnol. 3(3), 131–132 (2008)
52. F. Gu, L. Zhang, B.A. Teply, N. Mann, A. Wang, A.F. Radovic-Moreno et al., Precise
engineering of targeted nanoparticles by using self-assembled biointegrated block copolymers. Proc. Natl. Acad. Sci. U.S.A. 105(7), 2586–2591 (2008)
53. H. Shmeeda, D. Tzernach, L. Mak, A. Gabizon, Her2-targeted pegylated liposomal
doxorubicin: retention of target-specific binding and cytotoxicity after in vivo passage.
J. Control Release 136(2), 155–160 (2009)
54. J.H. Park, G. von Maltzahn, L.L. Zhang, A.M. Derfus, D. Simberg, T.J. Harris et al.,
Systematic surface engineering of magnetic nanoworms for in vivo tumor targeting. Small
5(6), 694–700 (2009)
55. S. Jeong, J.Y. Park, M.G. Cha, H. Chang, Y.I. Kim, H.M. Kim et al., Highly robust and
optimized conjugation of antibodies to nanoparticles using quantitatively validated protocols.
Nanoscale 9(7), 2548–2555 (2017)
56. D. Zeng, N.S. Lee, Y. Liu, D. Zhou, C.S. Dence, K.L. Wooley et al.,
64
Cu core-labeled
nanoparticles with high specific activity via metal-free click chemistry. ACS Nano 6(6),
5209–5219 (2012)
57. S.B. Lee, H.L. Kim, H.J. Jeong, S.T. Lim, M.H. Sohn, D.W. Kim, Mesoporous silica
nanoparticle pretargeting for PET imaging based on a rapid bioorthogonal reaction in a living
body. Angew. Chem. Int. Ed. Engl. 52(40), 10549–10552 (2013)
58. W.G. Kreyling, A.M. Abdelmonem, Z. Ali, F. Alves, M. Geiser, N. Haberl et al., In vivo
integrity of polymer-coated gold nanoparticles. Nat. Nanotechnol. 10(7), 619–623 (2015)
12 Click Chemistry for Radionanomedicine Platform
249